Sirona Biochem Announces Stock Options Exercise Price Revision
November 13 2012 - 4:33PM
Marketwired
Sirona Biochem Corp. (TSX
VENTURE:SBM)(PINKSHEETS:SRBCF)(FRANKFURT:ZSB) announced today it
has revised the exercise price of incentive stock option grants
issued October 11, 2012 and October 18, 2012. The exercise price of
these stock option grants has been revised from $0.07 to $0.10 per
share.
The exercise price revision, from $0.07 to $0.10 per share,
relates to 2,000,000 stock options granted to Neil Belenkie and
400,000 stock options granted to Nigel Terrett in connection with
their appointments as Chief Executive Officer and Strategic
Advisor, respectively. The original press releases announcing the
stock option grants were issued October 11, 2012 and October 18,
2012.
About Sirona Biochem Corp.
Sirona Biochem is a biotechnology company developing diabetes
therapeutics, cancer vaccine antigens, skin depigmenting and
anti-aging agents for cosmetic use, and biological ingredients. The
company utilizes a proprietary chemistry technique to improve
pharmaceutical properties of carbohydrate-based molecules. For more
information, visit www.sironabiochem.com.
Sirona Biochem cautions you that statements included in this
press release that are not a description of historical facts may be
forward-looking statements. Forward-looking statements are only
predictions based upon current expectations and involve known and
unknown risks and uncertainties. You are cautioned not to place
undue reliance on these forward-looking statements, which speak
only as of the date of release of the relevant information, unless
explicitly stated otherwise. Actual results, performance or
achievement could differ materially from those expressed in, or
implied by, Sirona Biochem's forward-looking statements due to the
risks and uncertainties inherent in Sirona Biochem's business
including, without limitation, statements about: the progress and
timing of its clinical trials; difficulties or delays in
development, testing, obtaining regulatory approval, producing and
marketing its products; unexpected adverse side effects or
inadequate therapeutic efficacy of its products that could delay or
prevent product development or commercialization; the scope and
validity of patent protection for its products; competition from
other pharmaceutical or biotechnology companies; and its ability to
obtain additional financing to support its operations. Sirona
Biochem does not assume any obligation to update any
forward-looking statements except as required by law.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Contacts: Sirona Biochem Corp. Julie Jang Director,
Communications 604.282.6065jjang@sironabiochem.com
www.sironabiochem.com
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sirona Biochem (TG:ZSB)
Historical Stock Chart
From Apr 2023 to Apr 2024